Status:
COMPLETED
Evaluation of the Haemostatic Agent Purabond in ENT TORS
Lead Sponsor:
University Hospital Birmingham NHS Foundation Trust
Conditions:
Hemorrhage
Eligibility:
All Genders
Brief Summary
To evaluate the use of Purabond in ENT TORS for diagnostic and therapeutic procedures. Consecutive patients enrolled retrospectively via case note review. Outcome measures - primary and secondary haem...
Detailed Description
Transoral robotic surgery (TORS) has been increasingly utilised in ear, nose and throat (ENT) Surgery over the past 20 years offering unprecedented 3-dimensional (3-D) views and enabling access to tra...
Eligibility Criteria
Inclusion
- all consecutive patients undergoing ENT transoral robotic surgery (TORS) with Purabond application between August 2021 - May 2022 at a single centre teaching university hospital NHS trust
Exclusion
- Purabond not applied
- incomplete case notes
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05405907
Start Date
August 1 2021
End Date
May 1 2022
Last Update
June 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Birmingham NHS Trust
Birmingham, United Kingdom, B15 2TH